P. Bombaron

Hôpital Privé Jean Mermo — France

Medicine · Health Sciences

12h-index5.9kcitations51works7.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(31), Cancer Immunotherapy and Biomarkers(14), Lung Cancer Diagnosis and Treatment(11), Multiple and Secondary Primary Cancers(9), Lung Cancer Research Studies(8)

Publications51 total

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
OncoImmunology·2025· 4 citedOpen Access
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer
Journal of Thoracic Oncology·2024· 10 citedOpen Access
78P Final analysis of the French real-world study EVIDENS: Effectiveness, safety & quality of life at 36 months of nivolumab in advanced non-small cell lung cancer (NSCLC)
Immuno-Oncology Technology·2023Open Access
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer
Journal of Thoracic Oncology·2023· 69 citedOpen Access
Analyse finale de l’étude EVIDENS par région française : survie et tolérance en vie réelle à 3 ans des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) traités par nivolumab
Revue des Maladies Respiratoires Actualités·2023
37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
Annals of Oncology·2022· 7 cited
EVIDENS : première analyse par région française des données de vie réelle de la prise en charge des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) traités par nivolumab
Revue des Maladies Respiratoires Actualités·2021
1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)
Annals of Oncology·2021
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
Lung Cancer·2021· 23 citedOpen Access
1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)
Annals of Oncology·2020
Cancers bronchiques non à petites cellules avec mutation HER2 : étude du microenvironnement immunitaire et efficacité des anti-PD-1
Revue des Maladies Respiratoires Actualités·2020
Efficacité et tolérance du nivolumab dans le traitement des patients (pts) atteints de cancer du poumon en France : analyse de survie et de sous-groupes de l’étude de vraie vie EVIDENS
Revue des Maladies Respiratoires Actualités·2020
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
OncoImmunology·2020· 38 citedOpen Access
Comparaison du micro-environnement tumoral de tumeurs bronchiques non à petites cellules et de métastases cérébrales : implications pour l’immunothérapie
Revue des Maladies Respiratoires Actualités·2020
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Annals of Oncology·2019· 2 cited
Compliance to Regional Recommendations for Molecular Analyses And Management of Advanced Lung Cancer Patients
Future Oncology·2019· 5 cited
Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
Annals of Oncology·2019· 5 citedOpen Access
Résultats de l’analyse intermédiaire de l’étude EVIDENS : patients atteints de cancer bronchopulmonaire traités par nivolumab en condition de vie réelle en France
Revue des Maladies Respiratoires·2018
EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
Annals of Oncology·2018· 1 citedOpen Access
Caractéristiques des patients atteints de cancer bronchopulmonaire non à petites cellules (CBNPC) traités par nivolumab en condition de vie réelle : première analyse de l’étude EVIDENS ( lung cancer patients treated with nivolumab : a longitudinal, prospective, observational, multicentric study )
Revue des Maladies Respiratoires·2018· 1 cited
page 1 of 3Next →

Frequent Co-authors

M. Pérol(21), D. Debieuvre(17), Fabrice Barlési(16), Bernard Asselain(16), A. Dixmier(14), C. Raspaud(14), J.B. Auliac(14), Denis Moro‐Sibilot(14), Clarisse Audigier-Valette(14), P. Fournel(11), L. Gérinière(9), G. Robinet(8), Nicolas Benoît(8), C. Calvet(7), P. Lamoureux(6), Victoria Allan(6), D. Reynaud(6), C. Chouaïd(6), FE Cotté(6), A. Vergnenègre(5)